Russell Mapes

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

James R. Berenson, Hank H. Yang, Karen Sadler et al. · Journal of Clinical Oncology · 2006 · 212 citations

A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

James R. Berenson, Jeffrey Matous, Regina A. Swift et al. · Clinical Cancer Research · 2007 · 122 citations · Full text

A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

James R. Berenson, Ori Yellin, Ravi Patel et al. · Clinical Cancer Research · 2009 · 44 citations

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

James R. Berenson, Hank H. Yang, Robert Vescio et al. · Annals of Hematology · 2008 · 42 citations

Phase 1/2, Hematological Malignancy, Melphalan Combination +7

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

James R. Berenson, Ori Yellin, Chien‐Shing Chen et al. · British Journal of Haematology · 2011 · 31 citations